Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Vanlev

Executive Summary

Twenty-five thousand patient OCTAVE trial will generate data by the end of the second quarter of 2001 that could support a resubmission of the Vanlev NDA, Bristol says. Bristol hopes to show equivalence between Vanlev (omapatrilat) and Merck's ACE inhibitor Vasotec (enalapril) in incidence of angioedema. The company withdrew the NDA for Vanlev in April in response to FDA's concerns about the side effect (1"The Pink Sheet" April 24, p. 8)

You may also be interested in...



Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn

Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel